A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT04951609
- Locations
- ๐บ๐ธ
CincyScience, West Chester, Ohio, United States
๐บ๐ธSouthwest Autism Research and Resource Center, Phoenix, Arizona, United States
๐บ๐ธYale University, New Haven, Connecticut, United States
A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Bronchoscopic BiopsyOther: Blood Sample
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT04951154
- Locations
- ๐บ๐ธ
Medstar Washington Hospital Center, Washington, District of Columbia, United States
๐บ๐ธRoswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
- Conditions
- Adenomatous Polyposis Coli
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04948398
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
- Conditions
- Arthritis, Psoriatic
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 453
- Registration Number
- NCT04936308
- Locations
- ๐บ๐ธ
DJL Clinical Research, PLLC, Charlotte, North Carolina, United States
๐บ๐ธArthritis and Rheumatology Center of MI, Okemos, Michigan, United States
๐บ๐ธClinical Research Institute of Michigan, LLC, Saint Clair Shores, Michigan, United States
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 405
- Registration Number
- NCT04929210
- Locations
- ๐ง๐ฌ
UMHAT Kaspela, Plovdiv, Bulgaria
๐ง๐ฌMedical Center Artmed, Plovdiv, Bulgaria
๐ง๐ฌMHAT 'Lyulin' EAD, Sofia, Bulgaria
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT04923893
- Locations
- ๐ฆ๐ท
Hospital Privado Universitario De Cordoba, Cordoba, Argentina
๐ต๐ฑNarodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach, Gliwice, Poland
๐ต๐ฑCentrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli, Lublin, Poland
A Study of JNJ-69095897 in Healthy Participants
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04920578
- Locations
- ๐ณ๐ฑ
Centre for Human Drug Research, Leiden, Netherlands
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 163
- Registration Number
- NCT04919512
- Locations
- ๐ง๐ช
Hopital de Jolimont, Haine Saint Paul La Louviere, Belgium
๐ง๐ชZNA Jan Palfijn, Merksem, Belgium
๐ง๐ชCentre Interuniversitaire Ambroise Pare - Ambroise Parรฉ, Mons, Belgium
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 327
- Registration Number
- NCT04914429
- Locations
- ๐จ๐ณ
Beijing Tongren Hospital, CMU, Beijing, China
๐จ๐ณXiangya Hospital Central South University, Changsha, China
๐จ๐ณShanghai Ruijin Hospital, Shanghai, China
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04911543
- Locations
- ๐ง๐ช
UZ Leuven Gasthuisberg, Leuven, Belgium